Adaptimmune Therapeutics plc Long-Term Debt 2011-2026 | ADAP

Long-term debt is a financial obligation of a company or an individual with a repayment period exceeding one year from the date it arises. In accounting, such obligations are recorded under the "long-term liabilities" section.

Main characteristics:

Term exceeds 12 months
Can take the form of bonds, bank loans, credit lines, leasing, or loans from affiliated parties
Repaid through regular payments (interest and/or principal) over several years

Why long-term debt is needed:

Investment in development
Allows financing of large projects — new factories, production lines, innovative developments — without diverting working capital.
Smoothing of cash flows
A long-term payment schedule facilitates budget planning and reduces short-term financial risks.
Optimization of capital structure
A combination of equity and borrowed capital can reduce the average cost of business financing.

A high level of long-term debt may indicate that a company heavily relies on borrowed funds. This increases risks, especially in conditions of rising interest rates or declining profits. However, a moderate level of debt can signal a sound growth strategy — for example, the company takes a loan to expand its business.

If a company uses borrowed funds effectively (e.g., invests in profitable projects), this can lead to profit growth and, consequently, an increase in stock value. An investor evaluates whether the investments made using debt are paying off.

It is important to monitor whether the company can regularly pay interest and repay the principal. Payment difficulties can lead to reduced dividends, a drop in stock value, and even bankruptcy.

Examples of long-term debt:

Mortgage loans for property purchases
Corporate bonds issued by a company to raise capital
Project financing — long-term loans for building or expanding production facilities
Leasing obligations for equipment or transport

Annual Long-Term Debt Adaptimmune Therapeutics plc

2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
19.9 M	20.3 M	23.1 M	20.9 M	23 M	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
23.1 M	19.9 M	21.5 M

Quarterly Long-Term Debt Adaptimmune Therapeutics plc

2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
25.7 M	25.4 M	50.2 M	49.9 M	25 M	18.4 M	19.9 M	20.5 M	21.6 M	20 M	20.3 M	19.9 M	-	23.2 M	23.1 M	23.7 M	19.7 M	19.9 M	20.9 M	20.9 M	20.9 M	20.9 M	23 M	23 M	23 M	23 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
50.2 M	18.4 M	24.1 M

Long-Term Debt of other stocks in the Biotechnology industry

Issuer	Long-Term Debt	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	273 M	-	2.43 %	$ 254 M	Germany
Alector ALEC	9.32 M	$ 2.11	-13.17 %	$ 217 M	USA
Acer Therapeutics ACER	146 K	-	2.71 %	$ 14 M	USA
Axsome Therapeutics AXSM	118 M	$ 163.89	-	$ 8.15 B	USA
BridgeBio Pharma BBIO	2.01 B	$ 64.28	-3.31 %	$ 12.3 B	USA
I-Mab IMAB	68.2 M	-	-	$ 866 M	China
BioCardia BCDA	982 K	$ 1.37	5.81 %	$ 29 M	USA
Alexion Pharmaceuticals, Inc. ALXN	2.42 B	-	-	$ 40.3 B	USA
AgeX Therapeutics AGE	13.2 M	-	-10.17 %	$ 12.2 K	USA
Biophytis SA BPTS	1.83 M	-	-13.47 %	$ 169 M	France
Aeglea BioTherapeutics AGLE	4 M	-	-	$ 1.01 B	USA
Applied Genetic Technologies Corporation AGTC	9.12 M	-	-	$ 26.5 M	USA
EyeGate Pharmaceuticals, Inc. EYEG	278 K	-	-1.52 %	$ 24.7 M	USA
BioLineRx Ltd. BLRX	2.74 M	$ 2.82	-0.35 %	$ 908 M	Israel
Midatech Pharma plc MTP	4.76 M	-	-18.52 %	$ 27.3 M	Britain
BioMarin Pharmaceutical BMRN	436 K	$ 59.8	-3.13 %	$ 11.5 B	USA
Bristol-Myers Squibb Company BMY	42.8 B	$ 62.08	-0.46 %	$ 126 B	USA
Benitec Biopharma BNTC	495 K	$ 10.93	0.23 %	$ 450 M	USA
BioNTech SE BNTX	231 M	$ 109.33	-0.82 %	$ 27.2 B	Germany
Black Diamond Therapeutics BDTX	18.8 M	$ 2.38	-3.44 %	$ 131 M	USA
ARCA biopharma ABIO	755 K	-	1052.0 %	$ 415 M	USA
Acorda Therapeutics ACOR	167 M	-	-24.86 %	$ 820 K	USA
BioXcel Therapeutics BTAI	103 M	$ 1.63	-2.4 %	$ 4.13 M	USA
Acasti Pharma ACST	410 K	-	4.01 %	$ 150 M	Canada
Adverum Biotechnologies ADVM	86 M	-	-	$ 86.2 M	USA
Институт стволовых клеток человека ISKJ	175 M	-	-	-	Russia
AIkido Pharma AIKI	2.63 M	-	1.93 %	$ 17.4 M	USA
Akero Therapeutics AKRO	529 K	-	-	$ 3.67 B	USA
Akouos AKUS	28.3 M	-	0.23 %	$ 488 M	USA
BeyondSpring BYSI	2.17 M	$ 1.34	-0.87 %	$ 54 M	USA
Albireo Pharma ALBO	9.62 M	-	-0.23 %	$ 916 M	USA
Allena Pharmaceuticals ALNA	210 K	-	3.16 %	$ 1.9 M	USA
Cabaletta Bio CABA	1.46 M	$ 3.34	0.61 %	$ 3.9 M	USA
Aileron Therapeutics ALRN	69 K	-	10.36 %	$ 9.8 M	USA
AlloVir ALVR	16.6 M	-	4.14 %	$ 49.1 M	USA
Alpine Immune Sciences ALPN	3.38 M	-	-	$ 2.17 B	USA
Capricor Therapeutics CAPR	1.49 M	$ 27.28	-2.32 %	$ 731 M	USA
Aeterna Zentaris AEZS	31 K	-	5.93 %	$ 314 M	Canada
Ampio Pharmaceuticals AMPE	274 K	-	-11.43 %	$ 502 K	USA
Catalyst Biosciences CBIO	199 K	$ 11.67	-3.47 %	$ 768 M	USA
Applied Molecular Transport AMTI	49 K	-	-	$ 10.1 M	USA
Aravive ARAV	1.88 M	-	-13.39 %	$ 1.45 M	USA
C4 Therapeutics CCCC	53.6 M	$ 3.06	13.3 %	$ 254 M	USA
Aptose Biosciences APTO	193 K	-	-45.71 %	$ 1.2 M	Canada
Aptinyx APTX	22.1 M	-	-39.0 %	$ 4.57 M	USA
Athira Pharma ATHA	803 K	-	-	$ 269 M	USA
Codexis CDXS	28.9 M	$ 0.99	-2.04 %	$ 72.7 M	USA
Aridis Pharmaceuticals ARDS	1.29 M	-	17.91 %	$ 11.1 M	USA